Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia

ZHOU Ling; PENG Qiuyuan; ZHAO Pan; WEI Jin; LIN Xiaojing; ZOU Xingli; LUO Wenfeng; WANG Jing; XIE Kunying; LI Xianglong; LIU Yang; NI Xun

doi:10.6039/j.issn.1001-0408.2024.14.12

您当前的位置：

首页 >

文章列表页 >

Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia

更新时间：2025-09-23

- Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia
- ZHONGGUO YAOFANG Vol. 35, Issue 14, Pages: 1743-1747(2024)
- 作者机构：
  
  川北医学院附属医院血液科，四川南充　637000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.14.12
  CLC： R979.1;R733.71
- Received：03 January 2024，
  
  Revised：2024-06-15，
  
  Accepted：27 June 2024，
  
  Published：30 July 2024
- 稿件说明：
移动端阅览
周玲,彭秋媛,赵攀,等.维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病的临床观察 [J].中国药房,2024,35(14):1743-1747.

ZHOU Ling,PENG Qiuyuan,ZHAO Pan,et al.Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia[J].ZHONGGUO YAOFANG,2024,35(14):1743-1747.
周玲,彭秋媛,赵攀,等.维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病的临床观察 [J].中国药房,2024,35(14):1743-1747. DOI： 10.6039/j.issn.1001-0408.2024.14.12.

ZHOU Ling,PENG Qiuyuan,ZHAO Pan,et al.Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia[J].ZHONGGUO YAOFANG,2024,35(14):1743-1747. DOI： 10.6039/j.issn.1001-0408.2024.14.12.

摘要

目的

观察维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗急性髓系白血病（AML）的近期疗效和安全性。

方法

回顾性收集2022年10月至2023年11月我院收治的40例初诊AML患者资料，根据治疗方案分为观察组和对照组，每组20例。对照组患者给予注射用盐酸柔红霉素+注射用阿糖胞苷，观察组患者给予维奈克拉片+高三尖杉酯碱注射液+注射用阿糖胞苷。两组患者均以28 d为1个周期，诱导化疗1个周期后评价近期疗效、微小残留病（MRD）阴性率、粒细胞缺乏持续时间、血小板计数（PLT）＜20×10

－1

持续时间、悬浮红细胞输注量及血小板输注量，以及不良反应发生情况。

结果

观察组患者的完全缓解或完全缓解伴血液学不完全恢复（CR/CRi）率显著高于对照组（

＜0.05），且在CR/CRi患者中，观察组患者的MRD阴性率也显著高于对照组（

＜0.05）；但在低、中、高危患者中，两组患者的CR/CRi率比较，差异均无统计学意义（

＞0.05）。两组患者的粒细胞缺乏持续时间、PLT＜20×10

－1

持续时间、悬浮红细胞输注量、血小板输注量、血液学毒性反应发生率及非血液学毒性反应发生率比较，差异均无统计学意义（

＞0.05）。

结论

维奈克拉联合高三尖杉酯碱和阿糖胞苷治疗AML的近期疗效和安全性较均好。

Abstract

OBJECTIVE

To observe the short-term efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia （AML）.

METHODS

The data of 40 newly diagnosed AML patients admitted to our hospital from October 2022 to November 2023 were retrospectively collected and divided into observation group and control group according to treatment plan， with 20 cases in each group. The patients in the control group were given Daunorubicin hydrochloride for injection+Cytarabine for injection， and the patients in the observation group were given Venetoclax tablets+Homoharringtonine injection+Cytarabine for injection. The patients in both groups were given relevant medicine， with 28 days as one cycle. The short-term efficacy， negative rate of minimal residual disease （MRD）， duration of granulocyte deficiency， duration of platelet （PLT）＜20×10

－1

， transfusion volume of suspended red blood cells and platelet， and the occurrence of adverse drug reactions were evaluated in both groups after 1 cycle of induction chemotherapy.

RESULTS

The complete remission or complete remission with incomplete hematologic recovery （CR/CRi） rate in the observation group was significantly higher than control group （

＜0.05）， and the negative rate of MRD in the observation group was also significantly higher than control group （

＜0.05）. However， in low-， medium- and high-risk patients， there was no statistical significance in CR/CRi rates between the two groups （

＞0.05）. There were no significant differences in the duration of agranulocytosis， the duration of PLT ＜20×10

－1

， the amount of suspended red blood cell transfusion， the amount of platelet transfusion， the incidence of hematologic toxicity and the incidence of non-hematologic toxicity between 2 groups （

＞0.05）.

CONCLUSIONS

Venetoclax combined with homoharringtonine and cytarabine show good short-term efficacy and safety in the treatment of AML.

关键词

Keywords

references

SIEGEL R L ， MILLER K D ， FUCHS H E ， et al . Cancer statistics，2021 [J ] . CA Cancer J Clin ， 2021 ， 71 （ 1 ）： 7 - 33 .

JIMBU L ， VALEANU M ， TRIFA A P ， et al . A survival analysis of acute myeloid leukemia patients treated with intensive chemotherapy：a single center experience [J ] . Cureus ， 2023 ， 15 （ 8 ）： e43794 .

KANTARJIAN H ， O’BRIEN S ， CORTES J ， et al . Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome：predictive prognostic models for outcome [J ] . Cancer ， 2006 ， 106 （ 5 ）： 1090 - 1098 .

SAMRA B ， KONOPLEVA M ， ISIDORI A ， et al . Venetoclax-based combinations in acute myeloid leukemia：current evidence and future directions [J ] . Front Oncol ， 2020 ， 10 ： 562558 .

DINARDO C D ， JONAS B A ， PULLARKAT V ， et al . Azacitidine and venetoclax in previously untreated acute myeloid leukemia [J ] . N Engl J Med ， 2020 ， 383 （ 7 ）： 617 - 629 .

WANG H F ， MAO L P ， YANG M ， et al . Venetoclax plus 3+7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia：a multicentre，single-arm，phase 2 trial [J ] . Lancet Haematol ， 2022 ， 9 （ 6 ）： e415 - e424 .

中华医学会血液学分会白血病淋巴瘤学组 . 中国成人急性髓系白血病（非急性早幼粒细胞白血病）诊疗指南：2021年版 [J ] . 中华血液学杂志， 2021 ， 42 （ 8 ）： 617 - 623 .

Leukemia and Lymphoma Group，Chinese Society of Hematology，Chinese Medical Association . Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia（not APL）：2021 [J ] . Chin J Hematol ， 2021 ， 42 （ 8 ）： 617 - 623 .

张之南，沈悌 . 血液病诊断及疗效标准 [M ] . 3版 . 北京：科学出版社， 2007 ： 131 - 133 .

ZHANG Z N ， SHEN T . Diagnosis and efficacy criteria for hematological diseases [M ] . 3rd. Beijing ： Science Press ， 2007 ： 131 - 133 .

中华医学会血液学分会实验诊断学组 . 急性髓系白血病微小残留病检测与临床解读中国专家共识：2021年版 [J ] . 中华血液学杂志， 2021 ， 42 （ 11 ）： 889 - 897 .

Laboratory Diagnostics Group，Chinese Society of Hematology，Chinese Medical Association . Chinese consensus on minimal residual disease detection and interpretation of patients with acute myeloid leukemia：2021 [J ] . Chin J Hematol ， 2021 ， 42 （ 11 ）： 889 - 897 .

FREITES-MARTINEZ A ， SANTANA N ， ARIAS-SANTIAGO S ， et al . Using the common terminology criteria for adverse events （CTCAE - version 5.0） to evaluate the severity of adverse events of anticancer therapies [J ] . Actas Dermosifiliogr ， 2021 ， 112 （ 1 ）： 90 - 92 .

WALTER R B ， KANTARJIAN H M ， HUANG X L ， et al . Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia：a combined Eastern Cooperative Oncology Group，Southwest Oncology Group，and M. D. Anderson Cancer Center Study [J ] . J Clin Oncol ， 2010 ， 28 （ 10 ）： 1766 - 1771 .

JONGEN-LAVRENCIC M ， GROB T ， HANEKAMP D ， et al . Molecular minimal residual disease in acute myeloid leukemia [J ] . N Engl J Med ， 2018 ， 378 （ 13 ）： 1189 - 1199 .

范晨阳，许鑫欣，孙维龙，等 . 维奈克拉联合用药治疗急性髓细胞白血病作用机制的研究现状 [J ] . 国际输血及血液学杂志， 2021 ， 44 （ 5 ）： 376 - 382 .

FAN C Y ， XU X X ， SUN W L ， et al . Research status in mechanisms of venetoclax combined with other drugs for treatment of acute myeloid leukemia [J ] . Int J Blood Transfus Hematol ， 2021 ， 44 （ 5 ）： 376 - 382 .

MI R H ， ZHAO J ， CHEN L ， et al . Efficacy and safety of homoharringtonine for the treatment of acute myeloid leukemia：a meta-analysis [J ] . Clin Lymphoma Myeloma Leuk ， 2021 ， 21 （ 10 ）： e752 - e767 .

CORTES J E ， HEIDEL F H ， HELLMANN A ， et al . Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome [J ] . Leukemia ， 2019 ， 33 （ 2 ）： 379 - 389 .

DINARDO C D ， LACHOWIEZ C A ， TAKAHASHI K ， et al . Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia [J ] . J Clin Oncol ， 2021 ， 39 （ 25 ）： 2768 - 2778 .

KADIA T M ， REVILLE P K ， BORTHAKUR G ， et al . Venetoclax plus intensive chemotherapy with cladribine，idarubicin，and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodyspla-stic syndrome：a cohort from a single-centre，single-arm，phase 2 trial [J ] . Lancet Haematol ， 2021 ， 8 （ 8 ）： e552 - e561 .

尹昭 . 高三尖杉酯碱协同Venetoclax增强其联合方案的抗AML作用与机制研究 [D ] . 广州：南方医科大学， 2021 .

YIN Z . Synergistic effect of homoharringtonine and venetoclax on enhancing the anti-AML effect of their combined regimen and its mechanism [D ] . Guangzhou ： Sou-thern Medical University ， 2021 .

Views

319

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer

Clinical observation of vonoprazan-based triple therapy in treatment-naive patients with Helicobacter pylori infection

Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention

Related Author

WANG Wanwan

YE Jun

CHENG Hai

YAO Wei

LIU Guiling

LI Shanshan

ZHENG Jishan

CHEN Yanyan

Related Institution

Dept. of Hematology， the Third People’s Hospital of Bengbu

Dept. of Hematology， the Affiliated Hospital of Xuzhou Medical University

Dept. of Pharmacy， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Paediatrics， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Pharmacy， the Affiliated Hospital of Zunyi Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰